This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Korea Institute of Science and Technology, The Asan Foundation, University of Ulsan Foundation for Industry Cooperation. Active years: 2023.
Company Filing History:
1 out of 2,248 
1 out of 84 
1 out of 94 
Years Active: 2023
Title: Anna Ju - Innovator in Cancer Treatment
Introduction
Anna Ju is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of cancer treatment through her innovative research and development of genetically modified immunocytes.
Latest Patents
Anna Ju holds a patent for "Immunocytes expressing a chimeric antigen receptor binding to cancer cells and TNF-related apoptosis-inducing ligand (TRAIL)." This patent describes a genetically modified immunocyte that expresses a chimeric antigen receptor (CAR) specifically designed to bind to cancer cells and/or express TRAIL. The invention includes a composition for preventing or treating cancer, which comprises the immunocytes, a cell therapeutic agent, a method for providing information for cancer diagnosis, and a method for preparing the genetically modified immunocyte.
Career Highlights
Throughout her career, Anna has worked with esteemed organizations such as the Korea Institute of Science and Technology and the Asan Foundation. Her work has focused on advancing cancer therapies and improving patient outcomes through innovative solutions.
Collaborations
Anna has collaborated with notable colleagues, including Eunsung Jun and Mihue Jang, to further her research and development efforts in the field of cancer treatment.
Conclusion
Anna Ju is a trailblazer in the realm of cancer research, with her innovative patent and collaborative efforts paving the way for advancements in treatment options. Her work exemplifies the impact of innovation in healthcare.